Trials / Recruiting
RecruitingNCT06613009
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
A Phase 1 Multicenter, Open-label Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 190 (estimated)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of IBI3009 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of IBI3009.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI3009 | Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3009) |
Timeline
- Start date
- 2024-12-30
- Primary completion
- 2027-08-30
- Completion
- 2027-08-30
- First posted
- 2024-09-25
- Last updated
- 2025-02-11
Locations
10 sites across 2 countries: Australia, China
Source: ClinicalTrials.gov record NCT06613009. Inclusion in this directory is not an endorsement.